Drug intelligence / Profile preview

DW1024

Development stage: Preclinical
Lead developer: Dongwha Pharmaceutical
Modality: Small Molecules

Overview

DW1024 is a novel small molecule therapeutic candidate under development by Dong-Wha Pharmaceutical for the treatment of immune-mediated diseases, including autoimmune and inflammatory disorders. It functions through a novel mechanism of action characterized by the regulation of immune responses and anti-inflammatory activity. Currently, the program is in the preclinical development stage, having successfully transitioned from the hit identification phase.

Targets

GPR119 (Glucose-dependent insulinotropic receptor)

Beyond the preview

Go deeper on DW1024.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DW1024.

Explore the full profile